Katelyn T. Byrne - Concepedia

Author

Katelyn T. Byrne

Also Known As

Byrne, Katelyn T., Katelyn T. Byrne, Katelyn Byrne, Katelyn T Byrne, Katelyn T. Byrne, Katelyn T. Byrne, Mary M Addison, Mary M. Addison, Matthew McWhorter

195

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Dartmouth College Parker Institute for Cancer Immunotherapy Cancer Research Institute Dana-Farber Cancer Institute

About

Katelyn T. Byrne is an author at University of Pennsylvania specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	2.7K
2	Immunology	13	13	2.4K
3	Cell Biology	8	8	1.4K
4	Health Sciences	1	1	18
5	Allergy	1	1	80

Katelyn T. Byrne

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy Jinyang Li, Katelyn T. Byrne, Fangxue Yan, Immunity Immune EvasionTumor ImmunologyCancer ImmunosurveillanceImmunologyTumor Immunity	2018	721
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma Rafael Winograd, Katelyn T. Byrne, Rebecca A. Evans, Cancer Immunology Research Immune Checkpoint MoleculesImmunologyImmune RegulationImmunoeditingImmunotherapeutics	2015	457
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Lacey Padrón, Deena M. Maurer, Mark H. O’Hara, Nature Medicine Randomized Phase 2Pancreatic CancerGastrointestinal OncologyMedicineImmunologic Analyses	2022	316
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, The Lancet Oncology Phase 1BPancreatic CancerMetastatic Pancreatic AdenocarcinomaMedicineImmunology	2020	286
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer Katelyn T. Byrne, Robert H. Vonderheide Cell Reports	2016	278
Resident memory T cells in the skin mediate durable immunity to melanoma Brian T. Malik, Katelyn T. Byrne, Jennifer L. Vella, Science Immunology	2017	269
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen Rebecca A. Evans, Mark S. Diamond, Andrew J. Rech, JCI Insight	2016	178
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Clinical Cancer Research	2021	170
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) Nune Markosyan, Jinyang Li, Yu Sun, Journal of Clinical Investigation ImmunologyImmune RegulationPtgs2 DeletionImmunoeditingImmunotherapeutics	2019	163
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40 Fan Yang, Zhenqiang He, Hao Duan, Nature Communications Synergistic ImmunotherapyImmunologyImmune RegulationImmunologic MechanismCd4 T Cell Responses	2021	147

Page 1